SG10201501285RA - Anti-alpha2 integrin antibodies and their uses - Google Patents

Anti-alpha2 integrin antibodies and their uses

Info

Publication number: SG10201501285RA
Authority: SG; Singapore
Prior art keywords: integrin antibodies; alpha2 integrin; alpha2; antibodies; integrin
Prior art date: 2010-02-23

Application number

SG10201501285RA

Inventor

Stanislas Blein

Samuel Hou

Darko Skegro

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-23

Filing date

2011-02-22

Publication date

2015-04-29

2011-02-22 Application filed by Sanofi Sa filed Critical Sanofi Sa

2015-04-29 Publication of SG10201501285RA publication Critical patent/SG10201501285RA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Zoology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Plant Pathology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)

SG10201501285RA 2010-02-23 2011-02-22 Anti-alpha2 integrin antibodies and their uses SG10201501285RA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30700910P	2010-02-23	2010-02-23

Publications (1)

Publication Number	Publication Date
SG10201501285RA true SG10201501285RA (en)	2015-04-29

Family

ID=44115556

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG2012061966A SG183431A1 (en)	2010-02-23	2011-02-22	Anti-alpha2 integrin antibodies and their uses
SG10201501285RA SG10201501285RA (en)	2010-02-23	2011-02-22	Anti-alpha2 integrin antibodies and their uses

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG2012061966A SG183431A1 (en)	2010-02-23	2011-02-22	Anti-alpha2 integrin antibodies and their uses

Country Status (14)

Country	Link
US (2)	US8975376B2 (en)
EP (3)	EP3590966A1 (en)
JP (4)	JP5972176B2 (en)
KR (2)	KR101712820B1 (en)
CN (1)	CN102933604B (en)
AU (2)	AU2011219496B2 (en)
BR (1)	BR112012021261A2 (en)
CA (2)	CA3027824A1 (en)
HK (1)	HK1209131A1 (en)
IL (2)	IL221615A (en)
MX (1)	MX2012009809A (en)
RU (2)	RU2015102845A (en)
SG (2)	SG183431A1 (en)
WO (1)	WO2011104604A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102933604B (en) *	2010-02-23	2016-04-06	赛诺菲	Anti-α 2 alpha 2 integrin antibodies and uses thereof
ES2865068T3 (en)	2011-01-14	2021-10-14	Univ California	Therapeutic antibodies to ROR-1 protein and methods of using them
PT2905335T (en) *	2012-10-03	2018-03-12	Chiome Bioscience Inc	Anti-human dlk-1 antibody having anti-tumor activity in vivo
FI3889173T3 (en)	2013-02-15	2023-10-02	Bioverativ Therapeutics Inc	Optimized factor viii gene
WO2014210209A2 (en) *	2013-06-27	2014-12-31	Abbvie Biotherapeutics Inc.	Fc variants with improved complement activation
KR102359214B1 (en)	2014-04-04	2022-02-07	델 마 파마슈티컬스	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
EP3160478A4 (en)	2014-06-30	2018-05-16	Bioverativ Therapeutics Inc.	Optimized factor ix gene
SI3411478T1 (en)	2016-02-01	2022-10-28	Bioverativ Therapeutics Inc.	Optimized factor viii genes
EP3883635A1 (en)	2018-11-19	2021-09-29	Progenity, Inc.	Methods and devices for treating a disease with biotherapeutics
EP4309722A3 (en)	2019-12-13	2024-08-07	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20220089767A1 (en)	2020-09-18	2022-03-24	Ichnos Sciences SA	Cd47-cd38 bispecific antibodies
WO2024001669A1 (en) *	2022-06-27	2024-01-04	昱言科技(北京)有限公司	Antibodies targeting itga2 and antibody-drug conjugates comprising same
WO2024126833A1 (en)	2022-12-16	2024-06-20	Ichnos Sciences SA	Cd47-il1rap bispecific antibodies

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
JPS6023084B2 (en)	1979-07-11	1985-06-05	味の素株式会社	blood substitute
WO1981001145A1 (en)	1979-10-18	1981-04-30	Univ Illinois	Hydrolytic enzyme-activatible pro-drugs
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en)	1981-08-31	1986-03-14	Genentech Inc	Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4675187A (en)	1983-05-16	1987-06-23	Bristol-Myers Company	BBM-1675, a new antibiotic complex
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en)	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en)	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
EP0206448B1 (en)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
WO1987005330A1 (en)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Method for enhancing glycoprotein stability
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
GB8610600D0 (en)	1986-04-30	1986-06-04	Novo Industri As	Transformation of trichoderma
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
GB8705477D0 (en)	1987-03-09	1987-04-15	Carlton Med Prod	Drug delivery systems
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971T2 (en)	1988-09-23	1996-09-05	Cetus Oncology Corp	CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
FR2646437B1 (en)	1989-04-28	1991-08-30	Transgene Sa	NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en)	1989-06-06	1990-12-12	Institut National De La Recherche Agronomique	Transformation vectors for yeast yarrowia
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0752248B1 (en)	1992-11-13	2000-09-27	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5858709A (en)	1996-10-15	1999-01-12	Smithkline Beecham P.L.C.	Fibronectin binding protein B compounds
US20020160970A1 (en)	1996-04-10	2002-10-31	Gyula Hadlaczky	Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6025155A (en)	1996-04-10	2000-02-15	Chromos Molecular Systems, Inc.	Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US7183387B1 (en) *	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
KR20060067983A (en)	1999-01-15	2006-06-20	제넨테크, 인크.	Polypeptide variants with altered effector function
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US7288390B2 (en)	2000-08-07	2007-10-30	Centocor, Inc.	Anti-dual integrin antibodies, compositions, methods and uses
US7074175B2 (en)	2001-07-25	2006-07-11	Erik Schroeder Handy	Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en)	2001-07-25	2006-02-14	Triton Biosystems, Inc.	Thermotherapy via targeted delivery of nanoscale magnetic particles
US20040002587A1 (en) *	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
US20060235208A1 (en) *	2002-09-27	2006-10-19	Xencor, Inc.	Fc variants with optimized properties
BR0316670A (en) *	2002-11-26	2005-10-11	Protein Design Labs Inc	Chimeric and humanized integrin (alpha) 5ß1 antibodies that modulate angiogenesis
CA2577370A1 (en) *	2004-08-16	2006-03-02	Medimmune, Inc.	Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
KR101027427B1 (en)	2004-11-12	2011-04-11	젠코어 인코포레이티드	Fc VARIANTS WITH INCREASED BINDING TO FcRn
DK1853718T3 (en)	2005-02-15	2015-11-09	Univ Duke	ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
AU2006230413B8 (en)	2005-03-31	2011-01-20	Xencor, Inc	Fc variants with optimized properties
WO2007041635A2 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en)	2005-10-06	2007-04-19	Xencor, Inc.	Optimized anti-cd30 antibodies
JP5583908B2 (en) *	2005-10-21	2014-09-03	ジェンザイム・コーポレーション	Antibody-based therapeutics with enhanced ADCC activity
US8231971B2 (en) *	2005-11-16	2012-07-31	UNIVERSITé LAVAL	Process for producing anti-fog coating
CN101360826B (en)	2005-11-18	2014-04-30	格兰马克药品股份有限公司	Anti-alpha2 integrin antibodies and their uses
WO2007106707A2 (en)	2006-03-10	2007-09-20	Macrogenics, Inc.	Identification and engineering of antibodies with variant heavy chains and methods of using same
WO2008140603A2 (en) *	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008090959A1 (en)	2007-01-24	2008-07-31	Kyowa Hakko Kirin Co., Ltd.	Genetically recombinant antibody composition having enhanced effector activity
GB0702888D0 (en)	2007-02-14	2007-03-28	Glaxo Group Ltd	Novel Antibodies
MX2009008754A (en)	2007-02-14	2009-11-02	Glaxo Group Ltd	Novel antibodies against igf-ir.
US20100184959A1 (en)	2007-03-19	2010-07-22	Medimmune Limited	Polypeptide Variants
PT2170389E (en) *	2007-06-12	2015-02-10	Genentech Inc	Humanized antibodies to amyloid beta
US8815237B2 (en) *	2007-12-05	2014-08-26	Massachusetts Institute Of Technology	Aglycosylated immunoglobulin mutants
WO2010085682A2 (en) *	2009-01-23	2010-07-29	Biogen Idec Ma Inc.	Stabilized fc polypeptides with reduced effector function and methods of use
BRPI1005984A2 (en) *	2009-02-23	2016-10-04	Glenmark Pharmaceuticals Sa	humanized antibody or fragment thereof that binds to human cd19, isolated nucleic acid, vector, host cell, method for producing a humanized antibody or fragment thereof that binds to human cd12, composition, immunoconjugate, use of humanized antibody or fragment of the same, article of manufacture and kit
EP2445520A4 (en)	2009-06-22	2013-03-06	Medimmune Llc	ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US8362210B2 (en)	2010-01-19	2013-01-29	Xencor, Inc.	Antibody variants with enhanced complement activity
CN102933604B (en)	2010-02-23	2016-04-06	赛诺菲	Anti-α 2 alpha 2 integrin antibodies and uses thereof

2011
- 2011-02-22 CN CN201180020557.6A patent/CN102933604B/en active Active
- 2011-02-22 SG SG2012061966A patent/SG183431A1/en unknown
- 2011-02-22 EP EP19173624.8A patent/EP3590966A1/en active Pending
- 2011-02-22 EP EP11714394.1A patent/EP2539370B1/en active Active
- 2011-02-22 KR KR1020147020779A patent/KR101712820B1/en active IP Right Grant
- 2011-02-22 CA CA3027824A patent/CA3027824A1/en not_active Abandoned
- 2011-02-22 RU RU2015102845/10A patent/RU2015102845A/en not_active Application Discontinuation
- 2011-02-22 CA CA2790866A patent/CA2790866C/en not_active Expired - Fee Related
- 2011-02-22 KR KR1020127024656A patent/KR101578686B1/en active IP Right Grant
- 2011-02-22 JP JP2012554433A patent/JP5972176B2/en active Active
- 2011-02-22 US US13/578,921 patent/US8975376B2/en active Active
- 2011-02-22 MX MX2012009809A patent/MX2012009809A/en active IP Right Grant
- 2011-02-22 RU RU2012140445/10A patent/RU2545401C2/en not_active IP Right Cessation
- 2011-02-22 WO PCT/IB2011/000344 patent/WO2011104604A2/en active Application Filing
- 2011-02-22 BR BR112012021261-3A patent/BR112012021261A2/en not_active IP Right Cessation
- 2011-02-22 SG SG10201501285RA patent/SG10201501285RA/en unknown
- 2011-02-22 EP EP14197411.3A patent/EP2848632B1/en active Active
- 2011-02-22 AU AU2011219496A patent/AU2011219496B2/en not_active Ceased
2012
- 2012-08-23 IL IL221615A patent/IL221615A/en not_active IP Right Cessation
2013
- 2013-06-18 HK HK15109116.3A patent/HK1209131A1/en unknown
2015
- 2015-01-28 US US14/607,345 patent/US11267891B2/en active Active
2016
- 2016-03-10 JP JP2016046699A patent/JP6276310B2/en active Active
2017
- 2017-07-05 AU AU2017204595A patent/AU2017204595A1/en not_active Abandoned
- 2017-09-13 IL IL254467A patent/IL254467A0/en unknown
2018
- 2018-01-10 JP JP2018001633A patent/JP6629890B2/en active Active
2019
- 2019-12-04 JP JP2019219224A patent/JP7050041B2/en active Active

Also Published As

Publication number	Publication date
CN102933604B (en)	2016-04-06
AU2011219496B2 (en)	2017-04-06
IL221615A (en)	2017-09-28
WO2011104604A2 (en)	2011-09-01
AU2017204595A1 (en)	2017-07-27
JP2018078901A (en)	2018-05-24
US20130052191A1 (en)	2013-02-28
US20150232559A1 (en)	2015-08-20
RU2015102845A (en)	2015-06-10
KR20150009948A (en)	2015-01-27
CA3027824A1 (en)	2011-09-01
HK1209131A1 (en)	2016-03-24
JP6276310B2 (en)	2018-02-07
US8975376B2 (en)	2015-03-10
IL254467A0 (en)	2017-11-30
JP6629890B2 (en)	2020-01-15
WO2011104604A3 (en)	2011-12-01
EP2539370A2 (en)	2013-01-02
SG183431A1 (en)	2012-09-27
EP2848632A1 (en)	2015-03-18
KR20120130773A (en)	2012-12-03
JP7050041B2 (en)	2022-04-07
BR112012021261A2 (en)	2020-01-07
CN102933604A (en)	2013-02-13
JP2016179971A (en)	2016-10-13
JP2020054360A (en)	2020-04-09
RU2015102845A3 (en)	2018-05-17
EP2848632B1 (en)	2019-07-10
JP2013520194A (en)	2013-06-06
AU2011219496A1 (en)	2012-09-27
RU2012140445A (en)	2014-03-27
KR101578686B1 (en)	2015-12-21
RU2545401C2 (en)	2015-03-27
EP3590966A1 (en)	2020-01-08
KR101712820B1 (en)	2017-03-22
CA2790866A1 (en)	2011-09-01
CA2790866C (en)	2019-02-12
US11267891B2 (en)	2022-03-08
JP5972176B2 (en)	2016-08-17
MX2012009809A (en)	2012-11-23
EP2539370B1 (en)	2019-05-15

Publication	Publication Date	Title
IL281250A (en)	2021-04-29	Anti-phf-tau antibodies and their uses
HRP20182098T1 (en)	2019-02-08	Anti-angptl3 antibodies and uses thereof
HK1216540A1 (en)	2016-11-18	Cd20 antibodies and uses thereof cd20
HUE057004T2 (en)	2022-04-28	Anti-cd277 antibodies and uses thereof
EP2494062A4 (en)	2013-05-29	Anti-glp-1r antibodies and their uses
ZA201107486B (en)	2012-06-27	Anti-tnf-x antibodies and their uses
IL225484A0 (en)	2013-06-27	Anti-cd48 antibodies and uses thereof
EP2756094A4 (en)	2015-05-06	Anti-b7-h4 antibodies and their uses
HK1179981A1 (en)	2013-10-11	Antibodies against il-18r1 and uses thereof il-18r1
HK1209131A1 (en)	2016-03-24	Anti-alpha2 integrin antibodies and their uses -2
EP2766382A4 (en)	2015-06-10	Meditopes and meditope-binding antibodies and uses thereof
EP2632949A4 (en)	2015-07-22	Clostridium difficile-specific antibodies and uses thereof
ZA201302537B (en)	2014-06-25	Stable and soluble antibodies
EP2632952A4 (en)	2014-04-30	Anti-sod1 antibodies and uses thereof
EP2593475A4 (en)	2014-03-05	Anti-addl monoclonal antibody and uses thereof
IL220536A0 (en)	2012-08-30	Anti - bv8 antibodies and uses thereof
EP2554552A4 (en)	2013-08-07	Novel anti-cd98 antibody and use thereof
IL214527A0 (en)	2011-09-27	Anti-mst1r antibodies and uses thereof
EP2620449A4 (en)	2014-03-26	Anti-ephrin-b2 antibody and use thereof
EP2545378A4 (en)	2013-11-13	Anti-lg3 antibodies and uses thereof
EP2578682A4 (en)	2014-01-08	Antibody and use thereof
LT2630159T (en)	2018-03-12	Stable and soluble antibodies
RS56862B1 (en)	2018-04-30	Stable and soluble antibodies